Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-984923 DDI Study with CYP Probe Substrates in Healthy Adults
NCT06632990Phase 1Active, not recruiting
- Sponsor
- Allyx Therapeutics
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-9894923 in Alzheimer's disease (AD) and Parkinson's disease (PD) (3 arms), sponsored by Allyx Therapeutics. Primary endpoints: Area under the curve for the first and last 96 hours of dosing at 24 days and Trough plasma drug concentration at steady state at 21 days. Started Nov 2024; status: active, not recruiting.
02
Drugs
BMS-9894923
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06632990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632990.